Brant Point Investment Management LLC Invests $4.11 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Brant Point Investment Management LLC purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,500 shares of the medical research company's stock, valued at approximately $4,106,000.

A number of other large investors have also made changes to their positions in the company. Metis Global Partners LLC lifted its stake in Bio-Rad Laboratories by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after acquiring an additional 30 shares in the last quarter. Signaturefd LLC boosted its holdings in Bio-Rad Laboratories by 13.2% during the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after purchasing an additional 31 shares during the last quarter. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Bio-Rad Laboratories by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock valued at $1,488,000 after buying an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after buying an additional 34 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada reiterated an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $380.20.

Bio-Rad Laboratories Stock Performance

BIO traded up $6.33 during trading hours on Wednesday, reaching $251.31. The company's stock had a trading volume of 90,422 shares, compared to its average volume of 315,243. The company's 50-day moving average is $252.93 and its 200-day moving average is $310.21. Bio-Rad Laboratories, Inc. has a 52 week low of $215.38 and a 52 week high of $387.99. The firm has a market cap of $7.04 billion, a PE ratio of -3.86 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.